Biomark Diagnostics Inc (BUX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 401 | 393 | 386 | 180 | 14 |
| Accounts receivable | -118 | -9 | 48 | -55 | -11 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | N/A | -82 |
| Other Working Capital | 5 | -86 | 138 | 43 | 240 |
| Other Operating Activity | -1,382 | -1,281 | -1,486 | -1,371 | -617 |
| Operating Cash Flow | $-1,093 | $-983 | $-914 | $-1,204 | $-456 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4 | -4 | -5 | -59 | N/A |
| Purchase Of Investment | N/A | N/A | N/A | 0 | -3 |
| Investing Cash Flow | $-4 | $-4 | $-5 | $-59 | $-3 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 0 | -325 | 85 | 150 | N/A |
| Debt Issued | N/A | N/A | N/A | 0 | 100 |
| Debt Repayment | -413 | -407 | -385 | -311 | -12 |
| Common Stock Issued | 3,611 | 1,542 | 603 | N/A | N/A |
| Other Financing Activity | 224 | 262 | 306 | 929 | 637 |
| Financing Cash Flow | $3,422 | $1,072 | $609 | $768 | $725 |
| Beginning Cash Position | 157 | 72 | 383 | 878 | 612 |
| End Cash Position | 2,482 | 157 | 72 | 383 | 878 |
| Net Cash Flow | $2,325 | $85 | $-311 | $-495 | $266 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,093 | -983 | -914 | -1,204 | -456 |
| Capital Expenditure | -4 | -4 | -5 | -59 | N/A |
| Free Cash Flow | -1,097 | -987 | -920 | -1,263 | -456 |